Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03317015 | A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR) | PHASE3 | COMPLETED | 260 | — | — | Nov 30, 2016 | Jul 10, 2017 | Apr 25, 2022 | - | — |
| Arm | Type | Description |
|---|---|---|
| Group A - Nasacort® | EXPERIMENTAL | Nasacort® will be sprayed twice in each nostril once every morning |
| Group B - Flixonase® | ACTIVE_COMPARATOR | Flixonase® will be sprayed twice in each nostril once every morning |
| Name | Type | Description |
|---|---|---|
| triamcinolone XRG5029 | DRUG | Pharmaceutical form: spray solution Route of administration: nasal |
| fluticasone | DRUG | Pharmaceutical form: spray solution Route of administration: nasal |
Inclusion criteria: * Females and males ≥18 and ≤50 years old. * Patients with previously diagnosed PAR with a positive skin prick test response to an appropriate allergen performed not earlier than 12 months prior to the Screening visit. * Patients must be clinically symptomatic (rTNSS reflecting ...